SCHEMBL6734565

SCHEMBL6734565

O=C(c1cnc(-c2cc[n+]([O-])cc2)nc1)N1CCN(S(=O)(=O)/C=C/c2ccc(Cl)cc2O)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
HTT P42858 1/20 0.38
F10 P00742 2/20 0.37
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GPR183 P32249 1/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA7 P43166 2/20 0.35
CA9 Q16790 2/20 0.35
CA14 Q9ULX7 2/20 0.35
HPGD P15428 1/20 0.35
FNTA P49354 3/20 0.34
FNTB P49356 3/20 0.34
ENPP2 Q13822 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6734568 1.00 ALDH1A1 (0.38) ALDH1A1HTTF10LMNAL3MBTL1
SCHEMBL6730261 0.88 ALDH1A1 (0.36) ALDH1A1HTTF10LMNAL3MBTL1
SCHEMBL6730258 0.88 ALDH1A1 (0.36) ALDH1A1HTTF10LMNAL3MBTL1
SCHEMBL6736801 0.82 ENPP2 (0.30) ENPP2
SCHEMBL6736794 0.82 ENPP2 (0.30) ENPP2
SCHEMBL6736796 0.82 LMNA (0.32) LMNA
SCHEMBL6737011 0.81 F10 (0.31) F10
SCHEMBL6737017 0.81 F10 (0.31) F10
SCHEMBL6730129 0.81 F10 (0.36) HTTF10LMNAKMT2AFNTA
SCHEMBL6730123 0.81 F10 (0.36) HTTF10LMNAKMT2AFNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 ALDH1A1 1316/4885HTT 2090/4885F10 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.